A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINO), in Patients With Advanced Solid Tumours.

Trial Profile

A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINO), in Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2011

At a glance

  • Drugs Cediranib (Primary) ; Ketoconazole
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Mar 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 21 Sep 2010 Planned end date changed from 1 Aug 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top